{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:29:00Z","timestamp":1783016940328,"version":"3.54.6"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-10408-x","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T12:17:26Z","timestamp":1735906646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Existing problems and new advice on stage criteria of natural history for chronic hepatitis B"],"prefix":"10.1186","volume":"25","author":[{"given":"Tongjing","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"issue":"4","key":"10408_CR1","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cld.2023.05.001","volume":"27","author":"C Boni","year":"2023","unstructured":"Boni C, Rossi M, Montali I, Tiezzi C, Vecchi A, Penna A, Doselli S, Reverberi V, Ceccatelli Berti C, Montali A, Schivazappa S, Laccabue D, Missale G, Fisicaro P. What Is the Current Status of Hepatitis B Virus Viro-Immunology? Clin Liver Dis. 2023;27(4):819\u201336. https:\/\/doi.org\/10.1016\/j.cld.2023.05.001.","journal-title":"Clin Liver Dis"},{"issue":"2 Suppl 1","key":"10408_CR2","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1002\/hep.20956","volume":"43","author":"HJ Yim","year":"2006","unstructured":"Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43(2 Suppl 1):S173\u201381. https:\/\/doi.org\/10.1002\/hep.20956.","journal-title":"Hepatology"},{"issue":"2","key":"10408_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"4","key":"10408_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399. https:\/\/doi.org\/10.1002\/hep.29800.","journal-title":"Hepatology"},{"issue":"1","key":"10408_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398. https:\/\/doi.org\/10.1007\/s12072-015-9675-4.","journal-title":"Hepatol Int"},{"key":"10408_CR6","unstructured":"Chinese liver disease association and Chinese Medical Association infectious disease branch: chronic hepatitis B Prevention Guide (2019 Edition). Chin J Infec. 2019;37(12):711\u2013736.\u00a0https:\/\/doi.org\/10.3760\/cma.j.issn.1000\u20136680.2019.12.003."},{"issue":"30","key":"10408_CR7","doi-asserted-by":"publisher","first-page":"10395","DOI":"10.3748\/wjg.v20.i30.10395","volume":"20","author":"CM Croagh","year":"2014","unstructured":"Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol. 2014;20(30):10395\u2013404. https:\/\/doi.org\/10.3748\/wjg.v20.i30.10395.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10408_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/hep.1840050315","volume":"5","author":"CM Chu","year":"1985","unstructured":"Chu CM, Karayiannis P, Fowler MJ, Monjardino J, Liaw YF, Thomas HC. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology. 1985;5(3):431\u20134. https:\/\/doi.org\/10.1002\/hep.1840050315.","journal-title":"Hepatology"},{"issue":"9663","key":"10408_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","volume":"373","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373(9663):582\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(09)60207-5.","journal-title":"Lancet"},{"issue":"1","key":"10408_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","volume":"22","author":"M Iannacone","year":"2022","unstructured":"Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol. 2022;22(1):19\u201332. https:\/\/doi.org\/10.1038\/s41577-021-00549-4.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10408_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1440-1746.2011.06940.x","volume":"27","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, Zhang JY, Wang LF, et al. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2012;27(2):223\u201330.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10408_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/cmi.2014.79","volume":"12","author":"A Bertoletti","year":"2015","unstructured":"Bertoletti A, Kennedy PT. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol. 2015;12(3):258\u201363.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"10408_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1053\/j.gastro.2015.11.050","volume":"150","author":"JJ Park","year":"2016","unstructured":"Park JJ, Wong DK, Wahed AS, et al. Hepatitis B research network hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology. 2016;150(3):684\u201395.","journal-title":"Gastroenterology"},{"issue":"4","key":"10408_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/apt.12590","volume":"39","author":"DT Chao","year":"2014","unstructured":"Chao DT, Lim JK, Ayoub WS, et al. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase 40 IU\/L and significant hepaticfibrosis. Aliment Pharmacol Ther. 2014;39(4):349\u201358.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10408_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1053\/j.gastro.2009.05.058","volume":"137","author":"M Kumar","year":"2009","unstructured":"Kumar M, Sarin SK. Hepatitis B virus immunotolerant patients: need to differentiate patients with or without liver disease. Gastroenterology. 2009;137(2):742\u20133.","journal-title":"Gastroenterology"},{"issue":"4","key":"10408_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jhep.2010.01.007","volume":"52","author":"T Nguyen","year":"2010","unstructured":"Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52(4):508\u201313.","journal-title":"J Hepatol"},{"issue":"8","key":"10408_CR17","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.cgh.2021.07.036","volume":"20","author":"P Martin","year":"2022","unstructured":"Martin P, Nguyen MH, Dieterich DT, Lau DT, Janssen HLA, Peters MG, Jacobson IM. Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update. Clin Gastroenterol Hepatol. 2022;20(8):1766\u201375.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10408_CR18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1053\/j.gastro.2016.11.057","volume":"152","author":"YF Liaw","year":"2017","unstructured":"Liaw YF, Chu CM. Immune tolerance phase of chronic hepatitis B. Gastroenterology. 2017;152(5):1245\u20136.","journal-title":"Gastroenterology"},{"issue":"2","key":"10408_CR19","first-page":"161","volume":"32","author":"W Wang","year":"2024","unstructured":"Wang W, Zhao CY. Rethinking the natural history staging for chronic hepatitis B virus infection[Article in Chinese]. Zhonghua Gan Zang Bing Za Zhi. 2024;32(2):161\u20133.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"7","key":"10408_CR20","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1016\/j.cgh.2022.08.039","volume":"21","author":"CM Chu","year":"2023","unstructured":"Chu CM, Liaw YF. Management of older patients with immunotolerant chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2023;21(7):1968\u20139. https:\/\/doi.org\/10.1016\/j.cgh.2022.08.039.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10408_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.coviro.2021.10.003","volume":"51","author":"KN Tsai","year":"2021","unstructured":"Tsai KN, Ou JJ. Hepatitis B virus e antigen and viral persistence. Curr Opin Virol. 2021;51:158\u201363. https:\/\/doi.org\/10.1016\/j.coviro.2021.10.003.","journal-title":"Curr Opin Virol"},{"issue":"4","key":"10408_CR22","doi-asserted-by":"publisher","first-page":"e1007690","DOI":"10.1371\/journal.ppat.1007690","volume":"15","author":"F Yang","year":"2019","unstructured":"Yang F, Yu X, Zhou C, Mao R, Zhu M, Zhu H, et al. Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. PLoS Pathog. 2019;15(4):e1007690. https:\/\/doi.org\/10.1371\/journal.ppat.1007690.","journal-title":"PLoS Pathog"},{"key":"10408_CR23","doi-asserted-by":"publisher","unstructured":"Li WT, Huang R, Wang J, Zhang BH, Wang QP, Feng J, Tongjing Xing TJ. Developement and validation of new predictive model for immune tolerance stage of chronic HBV infection based on liver histopathology. Hepatol Int. 2024;18:S128. https:\/\/doi.org\/10.1007\/s12072-024-10670-w.","DOI":"10.1007\/s12072-024-10670-w"},{"key":"10408_CR24","unstructured":"World Gastroenterology Organisation Global Guideline: Hepatitis B (Version 2.0). World Gastroenterology Organisation(WGO), 2015\u201302\u201301. https:\/\/www.worldgastroenterology.org\/guidelines\/hepatitis-b."},{"issue":"6","key":"10408_CR25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cgh.2010.03.006","volume":"8","author":"CM Chu","year":"2010","unstructured":"Chu CM, Chen YC, Tai DI, Liaw YF. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. Clin Gastroenterol Hepatol. 2010;8(6):535\u201340. https:\/\/doi.org\/10.1016\/j.cgh.2010.03.006.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10408_CR26","first-page":"1309","volume":"30","author":"Chinese Society of Hepatology","year":"2022","unstructured":"Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). Chin J Hepatol. 2022;30(12):1309\u201331.","journal-title":"Chin J Hepatol"},{"issue":"1","key":"10408_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/apt.15741","volume":"52","author":"HA Lee","year":"2020","unstructured":"Lee HA, Lee HW, Kim IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther. 2020;52(1):196\u2013204.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10408_CR28","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/s41598-020-58870-2","volume":"10","author":"JH Kim","year":"2020","unstructured":"Kim JH, Ghosh A, Ayithan N, et al. Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients. Sci Rep. 2020;10(1):1835. https:\/\/doi.org\/10.1038\/s41598-020-58870-2.","journal-title":"Sci Rep"},{"issue":"4","key":"10408_CR29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jhep.2010.01.007","volume":"52","author":"T Nguyen","year":"2010","unstructured":"Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini SA. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52(4):508\u201313. https:\/\/doi.org\/10.1016\/j.jhep.2010.01.007.","journal-title":"J Hepatol"},{"key":"10408_CR30","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/hep.23803","volume":"52","author":"HL Chan","year":"2010","unstructured":"Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 2010;52:1232\u201341.","journal-title":"Hepatology"},{"issue":"3","key":"10408_CR31","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/v13030368","volume":"13","author":"T Pollicino","year":"2021","unstructured":"Pollicino T, Caminiti G. HBV-integration studies in the clinic: role in the natural history of infection. Viruses. 2021;13(3):368. https:\/\/doi.org\/10.3390\/v13030368.","journal-title":"Viruses"},{"issue":"2","key":"10408_CR32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/hep.27609","volume":"61","author":"AM Di Bisceglie","year":"2015","unstructured":"Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61(2):703\u201311.","journal-title":"Hepatology"},{"issue":"05","key":"10408_CR33","doi-asserted-by":"publisher","first-page":"920","DOI":"10.19723\/j.issn.1671-167X.2022.05.019","volume":"54","author":"LJ Wang","year":"2022","unstructured":"Wang LJ, Li MW, Liu YN, et al. Natural history and disease progression of chronic hepatitis B virus infection. J Peking Univ (Health Sciences). 2022;54(05):920\u20136. https:\/\/doi.org\/10.19723\/j.issn.1671-167X.2022.05.019.","journal-title":"J Peking Univ (Health Sciences)"},{"key":"10408_CR34","unstructured":"WHO | Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[J]. World Health Organization; 2015. https:\/\/www.who.int\/publications\/i\/item\/9789241549059."},{"issue":"Suppl 4","key":"10408_CR35","doi-asserted-by":"publisher","first-page":"A80","DOI":"10.1016\/s0264-410x(02)00392-4","volume":"20","author":"LG Guidotti","year":"2002","unstructured":"Guidotti LG. The role of cytotoxic T cells and cytokines in the control of hepatitis B virus infection. Vaccine. 2002;20(Suppl 4):A80\u20132. https:\/\/doi.org\/10.1016\/s0264-410x(02)00392-4.","journal-title":"Vaccine"},{"issue":"1","key":"10408_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4049\/jimmunol.0902761","volume":"184","author":"S Phillips","year":"2010","unstructured":"Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol. 2010;184(1):287\u201395. https:\/\/doi.org\/10.4049\/jimmunol.0902761.","journal-title":"J Immunol"},{"issue":"5","key":"10408_CR37","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3390\/cells10051114","volume":"10","author":"SI Buschow","year":"2021","unstructured":"Buschow SI, Jansen DTSL. CD4+T cells in chronic hepatitis B and T cell-directed immunotherapy. Cells. 2021;10(5):1114.","journal-title":"Cells"},{"key":"10408_CR38","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1053\/j.gastro.2011.06.036","volume":"141","author":"CF Chen","year":"2011","unstructured":"Chen CF, Lee WC, Yang HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141:1240\u20138.","journal-title":"Gastroenterology"},{"issue":"8","key":"10408_CR39","first-page":"585","volume":"20","author":"RS Ying","year":"2012","unstructured":"Ying RS, Yang Z, Chen YY, et al. Differential liver histopathological features of chronic HBV infection patients with normal and mildly elevated serum ALT[Article in Chinese]. Zhonghua Gan Zang Bing Za Zhi. 2012;20(8):585\u20138.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"20","key":"10408_CR40","first-page":"30677","volume":"S1542\u20133565","author":"WJ Jeng","year":"2020","unstructured":"Jeng WJ, Lok AS. Should treatment indications for chronic hepatitis B be expanded? Clin Gastroenterol Hepatol. 2020;S1542\u20133565(20):30677\u201387.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10408_CR41","doi-asserted-by":"crossref","unstructured":"Hui CK, Leung N, Yuen ST, et al,\u00a0Hong Kong Liver Fibrosis Study Group. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007;46(2):395\u2013401.","DOI":"10.1002\/hep.21724"},{"issue":"5","key":"10408_CR42","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","volume":"67","author":"GA Kim","year":"2018","unstructured":"Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67(5):945\u201352.","journal-title":"Gut"},{"key":"10408_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejim.2020.10.022","volume":"84","author":"HW Lee","year":"2021","unstructured":"Lee HW, Chon YE, Kim BK, et al. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. Eur J Intern Med. 2021;84:68\u201373.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10408_CR44","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1038\/s41598-019-39043-2","volume":"9","author":"HW Lee","year":"2019","unstructured":"Lee HW, Kim SU, Baatarkhuu O, et al. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. Sci Rep. 2019;9(1):2508.","journal-title":"Sci Rep"},{"issue":"1","key":"10408_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00535-012-0668-y","volume":"48","author":"TC Tseng","year":"2013","unstructured":"Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol. 2013;48(1):13\u201321. https:\/\/doi.org\/10.1007\/s00535-012-0668-y.","journal-title":"J Gastroenterol"},{"key":"10408_CR46","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","volume":"66","author":"JH Kim","year":"2017","unstructured":"Kim JH, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, et al. Lowlevel viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2017;66:335\u201343.","journal-title":"Hepatology"},{"issue":"6","key":"10408_CR47","doi-asserted-by":"publisher","first-page":"850","DOI":"10.14218\/JCTH.2021.00046","volume":"9","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Peng H, Liu X, Wang H, Du J, Luo X, Ren H, Hu P. Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease. J Clin Transl Hepatol. 2021;9(6):850\u20139. https:\/\/doi.org\/10.14218\/JCTH.2021.00046.","journal-title":"J Clin Transl Hepatol"},{"issue":"7","key":"10408_CR48","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/jvh.13511","volume":"28","author":"K Yao","year":"2021","unstructured":"Yao K, Liu J, Wang J, Yan X, Xia J, Yang Y, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat. 2021;28(7):1025\u201333. https:\/\/doi.org\/10.1111\/jvh.13511.","journal-title":"J Viral Hepat"},{"issue":"21","key":"10408_CR49","doi-asserted-by":"publisher","first-page":"00069","DOI":"10.1016\/j.cgh.2021.01.019","volume":"S1542\u20133565","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, Li X, Le MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase. Clin Gastroenterol Hepatol. 2021;S1542\u20133565(21):00069. https:\/\/doi.org\/10.1016\/j.cgh.2021.01.019.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10408_CR50","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/jvh.13873","volume":"30","author":"QY Gan","year":"2023","unstructured":"Gan QY, Wang JX, Qian F, Wang YL, Huang Y, Zhang ZL, et al. Clinical and histological features of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat. 2023;30(10):803\u20139.","journal-title":"J Viral Hepat"},{"issue":"1","key":"10408_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cld.892","volume":"15","author":"JS Klair","year":"2020","unstructured":"Klair JS, Vancura J, Murali AR. PRO: patients with chronic hepatitis b in immune-tolerant phase should be treated. Clin Liver Dis (Hoboken). 2020;15(1):21\u20134.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"24","key":"10408_CR52","first-page":"00137","volume":"S0168\u20138278","author":"BC Narmada","year":"2024","unstructured":"Narmada BC, Khakpoor A, Shirgaonkar N, Narayanan S, Kim Aw PP, Singh M, et al. Single cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity. J Hepatol. 2024;S0168\u20138278(24):00137\u201345.","journal-title":"J Hepatol"},{"issue":"18","key":"10408_CR53","doi-asserted-by":"publisher","first-page":"e163175","DOI":"10.1172\/JCI163175","volume":"132","author":"MG Ghany","year":"2022","unstructured":"Ghany MG, Lok AS. Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA. J Clin Invest. 2022;132(18):e163175. https:\/\/doi.org\/10.1172\/JCI163175.","journal-title":"J Clin Invest"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10408-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10408-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10408-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T13:02:37Z","timestamp":1735909357000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10408-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10408"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10408-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}